MiMedx Group, Inc
MDXGMiMedx Group, Inc. is a healthcare company specializing in the development and commercialization of regenerative biomaterial products derived from human placental tissues. The company's products are used in wound care, orthopedics, and surgery to promote healing and tissue regeneration. MiMedx focuses on innovative biologic therapeutics supported by regenerative medicine research and has established a presence in healthcare markets worldwide.
Company News
MiMedx Group, Inc. announced it will report its fourth quarter and full year 2025 financial results on February 25, 2026, followed by a webcast and conference call with senior management at 4:30 p.m. Eastern Time to review the results.
MIMEDX marks the 15th anniversary of its flagship placental allograft products EPIFIX and AMNIOFIX, which have been featured in nearly 100 clinical and scientific publications including seven randomized controlled trials. The company positions these products as the industry's most studied placental allografts, used across multiple surgical specia...
MiMedx Group will report its third quarter 2025 financial results on October 29, 2025, with a webcast and conference call scheduled for 4:30 p.m. Eastern Time.
MiMedx Group will showcase its advanced wound care portfolio at the Symposium on Advanced Wound Care Fall meeting in Las Vegas, presenting six clinical and scientific posters focused on wound healing technologies and treatments.
MediWound has initiated a global Phase III trial to evaluate the efficacy and safety of its wound debridement therapy EscharEx for the treatment of venous leg ulcers. The trial aims to assess EscharEx's ability to effectively debride chronic wounds and prepare the wound bed for healing.
